Meyka Pro banner
Progress Software Corporation

Stay Updated with the Latest Progress Software Corporation PRGS News in Real Time

Find PRGS news now at Meyka AI. Stay informed with the latest Progress Software Corporation stocks updates, including price news, market analysis, and expert insights.

PRGSNASDAQ
TechnologySoftware - Infrastructure
$44.36
$1.15(2.66%)
U.S. Market opens in 61h 51m
Corus Entertainment Cuts More Jobs at Global News and Radio on August 21
📅 in about 2 hours

Corus Entertainment Cuts More Jobs at Global News and Radio on August 21

Corus Entertainment confirms fresh layoffs at Global B.C., Global National, News 640, and talk radio. Q3 revenue fell 16% and the company posted a $36.5M net loss.

Read more 12
Dodgers Catcher Dalton Rushing Targets September Return, Eyes Playoff Push
📅 in about 2 hours

Dodgers Catcher Dalton Rushing Targets September Return, Eyes Playoff Push

Dodgers catcher Dalton Rushing plans September catching return after partial UCL tear. Manager Dave Roberts had deemed his season return unlikely, but Rushing is progressing through throwing progression and targeting playoff readiness.

Read more 12
Gold Price Today: MCX Gold Jumps to ₹1,60,250. Why Gold Is Rising as Dollar Weakens, Fed Bets Shift
📅 11 hours ago

Gold Price Today: MCX Gold Jumps to ₹1,60,250. Why Gold Is Rising as Dollar Weakens, Fed Bets Shift

MCX gold price rose 0.52% to ₹1,60,250 on August 21, 2026, supported by a weaker dollar and falling US yields. September silver futures declined 1.02% to ₹2,45,736 on the same session. Healthy spot market demand and positive global cues drove bullion higher today. Brent crude slipped 0.27% to $93.52 a barrel, adding further support to…

Read more 12
AMD Shares Down 0.43% Despite Bullish $650 Price Target From Roth MKM
📅 11 hours ago

AMD Shares Down 0.43% Despite Bullish $650 Price Target From Roth MKM

AMD shares traded down 0.43% to $464.43 in early Thursday trading on August 20, 2026, even after Roth MKM reiterated a bullish call. The stock later reversed course, closing the session up 0.65% at $469.46. Analyst Suji Desilva maintained a Buy rating and $650 price target on the chipmaker. That target implies roughly $302 billion…

Read more 12
AI Investment Gets Boost as South Korea Plans New Fund From Chip Boom
📅 12 hours ago

AI Investment Gets Boost as South Korea Plans New Fund From Chip Boom

South Korea is looking to turn its semiconductor boom into a new source of AI investments. On August 21, 2026, the government announced plans for a Future Response Fund that would use excess tax revenue from the chip industry to support AI and other future technologies. Local media estimates put the potential size of the…

Read more 12
Bitcoin Surges Past $71,000 as Trump Backs Crypto Clarity Act, August 21
📅 1 day ago

Bitcoin Surges Past $71,000 as Trump Backs Crypto Clarity Act, August 21

Bitcoin surged past $71,000 on August 20 as falling US Treasury yields and Trump’s crypto meeting sparked a $2.7 billion short squeeze. The rally marks the coin’s highest level since early June.

Read more 12
Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update
📅 1 day ago

Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update

Moderna jumped 177% to $174.38 after Phase 3 melanoma vaccine trial success with Merck. The mRNA therapy reduced recurrence risk and represents the first approved late-stage cancer vaccine.

Read more 12
Moderna Soars 177% After Melanoma Vaccine Clears Late-Stage Trial on August 19
📅 1 day ago

Moderna Soars 177% After Melanoma Vaccine Clears Late-Stage Trial on August 19

Moderna jumps 177% and Merck gains 12% after their personalized mRNA cancer vaccine met key goals in a Phase 3 melanoma trial, the first positive late-stage result for an mRNA cancer therapy.

Read more 12
Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12%
📅 2 days ago

Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12%

Moderna jumped 177% and Merck rose 12% after announcing the first Phase 3 win for an mRNA cancer vaccine. The personalized treatment reduced melanoma recurrence risk significantly.

Read more 12

PRGS News FAQ